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Abstract 
Background: To analyze the spectrum of 
challenges faced in the treatment of Langerhen Cell 
Histiocytosis  resource limited settings lacking 
salvage therapy.   
Methods:  In this observational study , 42 patients 
of Langerhans cell histiocytosis were enrolled. Risk 
organ involvement, treatment course and outcome 
were analyzed.The patients were treated with 
vinblastine and prednisolone as first line given 
weekly for 6 weeks and then 3-weekly as a 
continuation therapy up to 6-12 months. Doses were 
calculated according to body surface area. 
Intravenous Cytarabine pulses used for 5 days 3-
weekly apart and Japanese Protocol used for 
refractory cases. The salvage therapy available in 
developed countries in the form of 2-CdA (2-
chlorodeoxyadenosine) and RIC -SCT reduced-
intensity conditioning stem cell transplantation not 
available in our center. In our study Group A 
include patients who refused enucleation and opted 
out of recommended treatment plan and Group B 
patients had enucleations done and followed 
treatment plans.  
Results:  Age of the patients range from< 1 to 10 
years (19% <2 yrs). M: F Ratio was 2:1. Majority 
(72%) of the  patients presented with multisystem-
LCH (MS-LCH) with100% mortality in MS-LCH 
group (p-value=0.045) and 18/42 (43%) had risk organ 
involvement with 72% mortality. Twenty nine (70%) 
had bone lesions and 12(29%) had central nervous 
system involvement. Fifty five percent completed 
treatment, 2/42 (5%) are on treatment, 9/42 (21%) 
abandoned treatment and 8/42 (19%) expired due to 
progressive disease and worsening infection. Sixteen 
 (38%) had reactivations of disease requiring therapy 
for more than one year. Twenty four percent of cases 
received two cycles of initiation therapy before 
continuation therapy started. The treatment initiated 
>6 months after the onset of symptoms in 30/42 
(72%) of cases with 100% expiries in this group and 
89% of abandonment.  The children presenting at 
younger age had risk of having MS-LCH 75% as 
compared to 36% in age >2years.   
Conclusion:  Treatment abandonment, delayed 
diagnosis and poor social support are major 
challenges in treating LCH in developing countries. 
Early diagnosis and timely treatment with effective 
infection control measures and strong social support 
are of utmost importance to improve long term 
overall survival. 
Key Words: Langerhans Cell Histiocytosis, 
Multiorgan , Chemotherapy  
Introduction 
Langerhans Cell Histiocytosis (LCH) is a relatively 
rare disease accounting for < 2% of new cases each 
year enrolled in The Children’s Hospital Lahore. LCH 
previously termed as histiocytosis X occurs primarily 
in childhood and is a rare clonal disorder of 
Langerhans cell proliferation, the antigen presenting 
immature dendritic cells that originate in bone 
marrow.1 The clinical manifestations vary widely from 
a self limiting unifocal bone lesion to a multi-system 
disease including rapidly fatal organ dysfunction. 
Currently LCH is classified as single-system (SS) and 
multisystem (MS) disease again divided in two groups 
depending on risk organ (RO), namely, liver, spleen 
and bone marrow involvement, RO-negative MS and 
RO-positive MS disease. 2, 3 The incidence of LCH is 4-
5 cases per million per year in children less than 15 
years with peak at less than 3 years of age. It is more 
common in boys than girls (1.2-2:1). LCH is usually 
sporadic though genetic predisposition may play a 
role as it is reported in twins and 1% of patients have 
relatives with LCH. 4 
For LCH diagnosis, histopathological examination is 
essential with histiocytes positive for CD1a or 
Langerin(CD207) on immunohistochemistry. Langerin 
is a cell surface receptor that triggers the formation of 
the Birbeck granules which are Langerhans cell-
specific  tennis racquet-shaped organelle detected by 
electron microscopy. Active LCH lesions contain LCH 
cells aggregates forming granulomas along with 
several inflammatory cells predominantly 
macrophages in later stages. When CD1a-positive cells 
show dysmorphic features and mitotic figures , 
Langerhans cell sarcoma should be excluded. 5, 6 The 
etiology of LCH has been debatable whether it is 
reactive based on the fact that these lesions sometimes 
show spontaneous regression and some virus DNA 
sequences have been found in blood and tissues of 
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LCH patients. 7,8. However , many facts support it as a 
neoplasm such as LCH cells are monoclonal  and they 
also sometimes  depict chromosomal deletion or gain 
more than 50% LCH patients, oncogenic BRAF V600E 
mutations are found associated with higher 
reactivation rate[11] though present in equal frequency 
in SS and MS LCH. 9-12 Treatment course of LCH is 
quite variable depending on the extent and risk organ 
involvement. The mortality is less in SS LCH or 
without risk organ involvement is <5 % and upto 10-
50% in MS LCH and RO positive disease. 13 
 
Patients and Methods 
In this observational study , conducted at the 
department of Paediatric Haematology/Oncology of 
the Children’s Hospital & the Institute of Child Health 
Lahore,42 patients of Langerhans Cell histiocytosis 
were enrolled , from January 2011 to December 2015. 
Data regarding their age, sex, classification, Risk organ 
involvement, treatment course and outcome 
analyzed.The patients were treated with vinblastine 
and prednisolone as first line given weekly for 6 weeks 
and then 3-weekly as a continuation therapy up to 6-12 
months Doses calculated according to body surface 
area. Intravenous Cytarabine pulses used for 5 days 3-
weekly apart and Japanese Protocol used for refractory 
cases. The salvage therapy available in developed 
countries in the form of 2-CdA (2-
chlorodeoxyadenosine) and RIC -SCT reduced-
intensity conditioning stem cell transplantation not 
available in our center. In our study Group A included 
patients who refused enucleation and opted out of 
recommended treatment plan and Group B patients 
had enucleations done and followed treatment plans.  
Results 
Total 42 patients with age ranging from< 1 to 10 years 
(19% <2 yrs) were included. M: F Ratio was 2:1. 
Majority (72%) patients presented with multisystem-
LCH (MS-LCH) with100% mortality in MS-LCH group 
(p-value=0.045) (Group A). Eighteen out of forty two  
(43%) had Risk Organ involvement with 63% mortality 
(Group B).  The treatment initiated >6 months after the 
onset of symptoms in 30/42 (72%) (Group C)of cases 
with 100% expiries in this group and 89% of 
abandonment (Table 1).Children presenting at 
younger age had risk of having Risk Organ 
involvement 75% as compared to 36% in age 
>2years(Table 2). Majority (70%) of patients had bone 
lesions. While 12/42(29%) had central nervous system 
(CNS) involvement.  Sixteen patients (38%) had 
reactivations of disease requiring therapy for more 
than one year. 24%of cases received two cycles of 
initiation therapy before continuation therapy started. 
Twenty three  (55%)  completed treatment, 2/42 (5%) 
are on treatment, 9/42 (21%) abandoned treatment 
and 8/42 (19%) expired due to progressive disease and 
worsening infection (Table: 3). 
Table 1: Outcome of High Risk Group 
Group  
A 
MS-
LCH(Multisystem) 
Expired: 8/8 
LAMA*: 6/9 
100% 
67% 
p-value 
0.380 
Group 
B  
RO+ (Risk Organ+) Expired: 5/8 
LAMA: 7/9 
62 % 
78% 
p-value 
0.020 
Group 
C 
Time Lag>6  
months 
Expired:8/8 
LAMA: 8/9 
100% 
89% 
p-value 
0.029 
*Left against medical advice  
Table: 2 Age Presentation 
Group A: <2 Years: 8 MS-LCH: 7/8  
88% 
SS-LCH: 1/8 
RO+: 6/8  75% 
RO-: 2/8 
Group B: >2 Years: 34 MS-LCH: 23/34 
68% 
SS-LCH: 11/34  
RO+: 12/34   
36% 
RO-: 22 
            p-value: 0.041  
Table 3: Langerhan Cell Histiocytosis – 
Treatment Outcomes (n=42) 
Parameter No % 
Treatment completed 23 55 
On treatment 2 05 
LAMA 9 21 
Expired at home 3 07 
Expired in hospital 5 12 
 
Discussion 
LCH can involve any organ or system with clinical 
manifestations in skin, CNS, bone, lung, liver, lymph 
nodes and haematological system with wide 
differential diagnoses confirmed by histological and 
immunophenotypic examination of the lesions in the 
form of positive CD1a and or CD207 (Langerin) for a 
definitive diagnosis.14 If the risk of biopsy is more than 
the need of definitive diagnosis, then effort should be 
made to exclude other conditions with similar 
radiological features and should be on close follow up. 
15 In our study 72% cases had their symptoms for more 
than six months before their diagnosis of LCH was 
made and definitive treatment started. 
The combination of Vinblastine and prednisolone is 
being used in LCH since 1966 and alone or with other 
chemotherapeutic agents these have been used in 
different prospective trials in MS-LCH in over 1000  
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Fig 1-4: Skin manifestations on scalp, palms and 
abdomen;Fig 5: CNS-Risk Lesion on Parieto-Occipital 
Region 
 
Fig 6: X-ray Skull Lateral view demonstrates bizarre ill-
defined lucencies involving upper parietal region;Fig 7: 
MRI saggital T1W image demonstrates isointense soft 
tissue mass at Parieto-occipital region;Fig 8: MRI lower 
limb T1W images showing heterogeneous signal 
intensities in left femoral diaphysis;Fig 9: T1W saggital 
MRI brain images demonstrate a soft tissue intensity 
lesion at vertex of the scalp with disrupted diploae spaces 
 
patients with excellent tolerability with overall success 
of at least 60 %.16 Therefore this combination can be 
used effectively in resource limited settings with 
success as it is cost effective and well tolerated as 
evidenced by LCH-III trials with 70% and 86% initial 
response in RO+ and RO- MS-LCH patients.17 In LCH-
IV, a large prospective trial, one of the focuses is to 
evaluate the role of second-line chemotherapeutic 
agents including cytarabine which minimize 
reactivations and permanent sequelae of LCH, a 
protocol which induces complete response and 
effective in neurodegenerative CNS-LCH. 
In refractory cases in risk –organ involvement it is 
suggested to be treated in specialized centers with a 
combination of cladribine (2-CdA and cytarabine (Ara-
C) and in non-risk organ cases 2-CdA can be used as a 
monotherapy or further courses of standard 
vinblastine and prednisolone combination , but 2CdA 
and RIC-SCT is not available in our center so few cases 
expired due to progression of disease not responded to 
standard therapy. 18-20 
LCH can be cured with standard chemotherapy in low 
income countries as described in Guatemala, El 
Salvador, Honduras, and Nicaragua with 57% well in 
remission ,16% on treatment , 24% abandonment and 
3% expiries as compared to our study showing 21% 
abandonment and 19% expiries due to progressive 
disease, advanced stages and superimposed infections. 
So the focus should be on minimizing the 
abandonment in LCH patients in low income 
countries. 21 
Reactivation is common in MS-LCH up to 50% cases 
with spontaneous recovery in some and requiring 
treatment in others with resolution. This reactivation is 
more common in first two years of disease onset and 
bone is more frequently involved than risk organs. It 
results in permanent sequelae also requiring close 
follow up and monitoring.22,23 In our study 38% of 
cases had reactivation of LCH and 62% among MS-
LCH requiring further treatment. These children need 
follow up and monitoring of permanent sequelae of 
different tissues like endocrinopathy (Diabetes 
Insipidus, Growth hormone deficiency, pubertal 
delay), orthopedic complications like scoliosis, hearing 
deficits requiring hearing aids, neuropsychological 
impairment (cerebellar ataxia, learning difficulties) 
and associated malignancies.24 These facilities are 
available in our center so these children are 
encouraged for long follow up and monitoring. 
 
Conclusion 
1. Delayed diagnosis. treatment abandonment and 
poor social support are major challenges in treatin 
LCH in developing countries. 2.Early diagnosis 
and timely treatment with effective infection 
control measures and strong social support are of 
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utmost importance to improve long term overall 
survival of these children being treated with 
standard chemotherapy. 
References 
1. Jon D, Laman JD , Pieter JM, Nicola E, Pancras CW. 
Langerhans cell Histiocytosis ‘Insight into DC biology. 
Trends Immunol.2003; 24:190-96. 
2. Morimoto A, Yukiko OH, Shiole Y. Recent Advances in 
Langerhans Cell Histiocytosis. Pediatrics International 2014; 
56: 451-61 
3. French Langerhans cell histiocytosis Study group, A 
multicenter retrospective survey of Langerhans cell 
histiocytosis: 384 cases observed between 1983 to 1993. 
Arch Dis Child 1996; 75: 17-24. 
4. Aricò, M and  Danesino C.  Langerhans' cell histiocytosis: is 
there a role for genetics? Haematologica-Pavia then Roma 
2001; 86(10): 1009-14. 
 
5. Jaffe R and  Weiss LM. Tumors derived from Langerhans 
cells. In: Swerdlow SH, Campo E, Harris NL et al.(eds) WHO 
Classification of Tumors, Tumors of Haematopoeitic and 
Lymphoid Tissues, 4th Edn.  IARC, Lyon, 2008; 358-60. 
6. Lau S K, Chu PG, Weiss LM. Immunohistochemical 
expression of Langerin in Langerhans cell histiocytosis and 
non-Langerhans cell histiocytic disorders.The American 
journal of surgical pathology.2008; 32(4): 615-19. 
7. Minkov M, Prosch H. Langerhans cell histiocytosis in 
neonates. Pediatr. Blood Cancer 2005; 45:802-07 
8. Murakami I, Matsushita M,Prosh H, Steiner M, Grios N. 
Merkel cell polyoma virus DNA sequence in peripheral 
blood and tissues from patients of Langerhans cell 
Histiocytosis. Hum. Pathol.2014; 45: 119-26. 
9. Willman CL, Busque L Griffith BB. Langerhans Cell 
histiocytosis- a clonal proliferative disease. N. Engl. J. Med. 
1994; 331: 154-60 
10. Murakami I, Gogusev J, Formert JC, Glorion C. Detection of 
molecular cytogenetic aberrations in Langerhans cell 
Histiocytosis of bone. Hum. Pathol.2002; 33: 555-60 
11. Satoh T, Smith A , Sarde A, Lu H, Mian S. B-RAF mutant 
alleles associated with Langerhans cell histiocytosis, a 
Granulomatous pediatric disease. PLoS ONE 2012; 7: 
e33891 
12. Berres ML, Lim KP, peter T, Price J. BRAF-V600E expression 
in precursor versus differentiated dendiritic cells defines 
clinically distinct LCH risk groups. J. Exp. Med. 2014; 211: 
669-83. 
13. Donadieu J, Egeler RM, Beller S, Thomas C. Langerhans cell 
histiocytosis: a clinical update In: Weitzman S, Egeler RM 
(eds). Histiocytic disorders of children and adults. 
Cambridge University Press, Cambridge, 2005: 95-129  
14. Swerdlow SH and Campo E . WHO Classification of Tumors 
of Haematopoetic and Lymphoid tissues, 4th edition. Lyon: 
IARC press; 2008. 
15. Haupt R, Minkov M,Astigaraga I. Langerhans Cell 
Histiocytosis: Guidelines for Diagnosis, Clinical work-up, 
and Treatment for patients till the Age of 18 Years. Pediatr 
Blood Cancer 2013;60: 175-84 
16. Lahey ME, Histiocytosis X. An analysis of prognostic factors. J 
Pediatr 1975: 87: 184-89  
17. Minkov M and Rodriguez- Galindo C. Treatment of 
Langerhans cell histiocytosis: It is time to learn from the past. 
British Journal of Haematology 2015; 171: 137-51 
18. Bernard F, Thomas C, Bertand Y, Munzer M. Multi-center 
pilot study of 2-chlorodeoxyadenosine and cytosine 
arabinoside combined chemotherapy in refractory 
Langerhans cell histiocytosis with haematological 
dysfunction. Eur J Cancer 2005; 41: 2682-89. 
19. Steiner M, Matthes-Martin S, Attarbaschi A. Improved 
outcome of treatment-resistant high-risk Langerhans cell 
histiocytosis after allogeneic stem cell transplantation with 
reduced-intensity Conditioning. Bone Marrow Transplant 
2005; 36: 215-25. 
20. Weitzman S, Braier J, Donadieu J. 2-chlorodeoxyadenosine 
(2-CdA) as salvage therapy for Langerhans cell histiocytosis 
(LCH). Results of the LCH-S-98 protocol of the Histiocyte 
Society. Pediatr Blood cancer 2009; 53: 1271-76. 
21. Gadner H, Grois N, Arico M, Broadbent V, Ceri A.. A 
randomized trial of treatment for Multisystem Langerhans 
cell histiocytosis. J Pediatr 2001; 138: 728-34. 
22. Minkov M, Steiner M, Potschger U, Arico M. Reactivations in 
Multisystem Langerhans cell histiocytosis: data of the 
international LCH registry. J Pediatr. 2008;153: 700- 
05. 
23. Morimoto A, Kobayashi R. Maeda M. Impact of reactivation 
on the sequelae of multisystem Langerhans cell histiocytosis 
patients. Pediatr. Blood cancer 2008; 50: 931-32 
24. Haupt R, Minkov M , Astigrraga I. Langerhans Cell 
Histiocytosis: Guidelines for Diagnosis, Clinical work-up, 
and Treatment for patients till the Age of 18 Years. Pediatr 
Blood Cancer 2013; 60: 175-84. 
 
 
